Horizant and Rashes - a phase IV clinical study of FDA data

Summary:

Rashes is reported as a side effect among people who take Horizant (gabapentin enacarbil), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Adderall, and have Immunodeficiency common variable.

The phase IV clinical study analyzes which people have Rashes when taking Horizant. It is created by eHealthMe based on reports of 1,979 people who have side effects when taking Horizant from the FDA, and is updated regularly.

What is Horizant?

Horizant has active ingredients of gabapentin enacarbil. It is often used in restless leg syndrome. eHealthMe is studying from 2,051 Horizant users. Check the latest studies of Horizant.

What is Rashes?

Rashes (redness) is found to be associated with 3,712 drugs and 6,213 conditions by eHealthMe. Check the latest studies of Rashes.

On Jul, 19, 2026

1,979 people reported to have side effects when taking Horizant.
Among them, 70 people (3.54%) have Rashes.

Among these 70 people:

How long have people been on Horizant when they have Rashes? *

What is the gender of people who have Rashes when taking Horizant? *

female: 75.86 %
male: 24.14 %

What is the age of people who have Rashes when taking Horizant? *

What are other drugs people take besides Horizant? *

What are other side effects people have besides Rashes? *

Urinary Tract Infection: 12 people, 17.14%
Oedema (fluid collection in tissue): 11 people, 15.71%
Fainting (loss of consciousness and postural tone): 11 people, 15.71%
Headache (pain in head): 9 people, 12.86%
Itching: 8 people, 11.43%
Infusion Site Extravasation (flow of (blood or lymph) from infusion site): 8 people, 11.43%
Infusion Site Pruritus (severe itching at infusion site): 8 people, 11.43%
Urticaria (rash of round, red welts on the skin that itch intensely): 8 people, 11.43%
Infection: 7 people, 10.00%
Hypersensitivity: 7 people, 10.00%

What are the existing conditions these people have? *

Immunodeficiency Common Variable: 12 people, 17.14%
Neuralgia (pain in one or more nerves): 6 people, 8.57%
Primary Immunodeficiency Syndrome: 4 people, 5.71%
Multiple Myeloma (cancer of the plasma cells): 4 people, 5.71%
Hypersensitivity: 4 people, 5.71%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 3 people, 4.29%
Pain: 3 people, 4.29%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 3 people, 4.29%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 3 people, 4.29%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 3 people, 4.29%

* Approximation only. Some reports may have incomplete information.

Do you take Horizant and have Rashes?

- Check whether Rashes is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Horizant:

Horizant (2,051 reports)

Rashes treatments and more:

Rashes (702,909 reports)

Browse all side effects of Horizant:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rashes:

Rashes (3,712 drugs)

Browse all the conditions that are associated with Rashes:

Rashes (6,213 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on gabapentin enacarbil (the active ingredients of Horizant) and Horizant (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.